Asset Details
Do you wish to reserve the book?
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Do you wish to request the book?
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
2011
Overview
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of complete response and freedom from relapse but also with more short-term and long-term toxic effects.
The regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was introduced in the mid-1970s as treatment for advanced Hodgkin's lymphoma
1
and became the standard of treatment for this disease after trials showed that ABVD was as effective as, or more effective than, the regimen of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), with fewer toxic effects.
2
More recently, the German Hodgkin Lymphoma Study Group (GHSG) has developed a front-line intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escalated BEACOPP regimen, which includes higher-than-standard doses of etoposide, doxorubicin, and cyclophosphamide). This regimen, as compared with COPP-ABVD, has been . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Cyclophosphamide - adverse effects
/ Cyclophosphamide - therapeutic use
/ Dacarbazine - adverse effects
/ Dacarbazine - therapeutic use
/ Disease
/ Doxorubicin - adverse effects
/ Doxorubicin - therapeutic use
/ Female
/ Hematopoietic Stem Cell Transplantation
/ Hodgkin Disease - drug therapy
/ Hodgkin Disease - radiotherapy
/ Humans
/ Lymphoma
/ Male
/ Patients
/ Prednisone - adverse effects
/ Prednisone - therapeutic use
/ Procarbazine - adverse effects
/ Procarbazine - therapeutic use
/ Survival
/ Vinblastine - adverse effects
/ Vinblastine - therapeutic use
/ Vincristine - adverse effects
